EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

LKB1 dictates sensitivity to immunotherapy through Skp2-mediated ubiquitination of PD-L1 protein in non-small cell lung cancer

Liting Lv, Qing Miao, Sutong Zhan, Peilin Chen, Wei Liu, Jiawen Lv, Wenjie Yan, Dong Wang, Hongbing Liu, Jie Yin, Jian Feng, Yong Song iD und 2 weitere

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2024-009444 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Liting Lv und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Jinling Hospital, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: AMP-Activated Protein Kinase Kinases, S-Phase Kinase-Associated Proteins, B7-H1 Antigen, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Shandong Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Loss-of-function mutations of liver kinase B ( LKB1 , also termed as STK11 ( serine/threonine kinase 11 )) are frequently detected in patients with non-small cell lung cancer (NSCLC). The LKB1 mutant NSCLC was refractory to almost all the antitumor treatments, including programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade therapy. Unfortunately, mechanisms underlying resistance to immunotherapy are not fully understood. In this study, we deciphered how LKB1 regulated sensitivity to anti-PD-1/PD-L1 immunotherapy.

Methods

We investigated the mutational landscape of LKB1 mutant NSCLC in next generation sequencing (NGS) data sets. Expression of LKB1, PD-L1 and S-phase kinase-associated protein 2 (Skp2) in NSCLC samples were assessed by immunohistochemistry (IHC). The tumor microenvironment (TME) profiling of LKB1 wild type (WT) and mutant NSCLC was performed using fluorescent multiplex IHC. Mass spectrometry and enrichment analysis were used to identify LKB1 interacting proteins. Mechanistic pathways were explored by immunoblotting, ubiquitination assay, cycloheximide chase assay and immunoprecipitation assay.

Results

By using NGS data sets and histological approaches, we demonstrated that LKB1 status was positively associated with PD-L1 protein expression and conferred a T cell-enriched “hot” TME in NSCLC. Patients with good responses to anti-PD-1/PD-L1 immunotherapy possessed a high level of LKB1 and PD-L1. Skp2 emerged as the molecular hub connecting LKB1 and PD-L1, by which Skp2 catalyzed K63-linked polyubiquitination on K136 and K280 residues to stabilize PD-L1 protein. Inhibition of Skp2 expression by short hairpin RNA or its E3 ligase activity by compound #25 abrogated intact expression of PD-L1 in vitro and generated a T cell-excluded “cold” TME in vivo. Thus, the LKB1-Skp2-PD-L1 regulatory loop was crucial for retaining PD-L1 protein expression and manipulation of this pathway would be a feasible approach for TME remodeling.

Conclusion

LKB1 and Skp2 are required for intact PD-L1 protein expression and TME remodeling in NSCLC. Inhibition of Skp2 resulted in a conversion from “hot” TME to “cold” TME and abrogated therapeutic outcomes of immunotherapy. Screening LKB1 and Skp2 status would be helpful to select recipients who may benefit from anti-PD-1/PD-L1 immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AMP-Activated Protein Kinase KinasesS-Phase Kinase-Associated ProteinsB7-H1 AntigenCarcinoma, Non-Small-Cell LungLung NeoplasmsDrug Resistance, NeoplasmUbiquitin-Protein LigasesHumansUbiquitinationLoss of Function MutationImmunotherapyImmune Checkpoint InhibitorsGene Expression Regulation, NeoplasticTumor MicroenvironmentBiomarkers, TumorCell Line, TumorSpecific Pathogen-Free OrganismsMice, Inbred C57BLMaleAnimalsMiceXenograft Model Antitumor AssaysFemaleMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsCohort Studies

Stichwörter der Autor:innen

Immune Checkpoint InhibitorImmunotherapyLung CancerNext generation sequencing - NGSTumor infiltrating lymphocyte - TIL

Substanzen

STK11 protein, humanAMP-Activated Protein Kinase KinasesSKP2 protein, humanS-Phase Kinase-Associated ProteinsCD274 protein, humanB7-H1 AntigenImmune Checkpoint InhibitorsBiomarkers, TumorUbiquitin-Protein Ligases

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Jinling Hospital, Nanjing Medical University, Nanjing, China.
  • Department of Oncology, Affiliated Hospital of Nantong University, Nantong, China.
  • Department of Pharmacy, the 971 Hospital of PLA Navy, Qingdao, China.
  • Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
  • Liaoning Kanghui Biotechnology Co. Ltd, Shenyang, China.
  • Department of Respiratory Medicine, Affiliated Hospital of Nantong University, Nantong, China.

ORCID-Profile: Yong Song, Mingxiang Ye

Förderung

  • Natural Science Foundation of Shandong Province
  • National Natural Science Foundation of China

Zitieren

APA

Lv, L., Miao, Q., Zhan, S., Chen, P., Liu, W., Lv, J., Yan, W., Wang, D., Liu, H., Yin, J., Feng, J., Song, Y., Ye, M., & Lv, T. (2024). LKB1 dictates sensitivity to immunotherapy through Skp2-mediated ubiquitination of PD-L1 protein in non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009444

Vancouver

Lv L, Miao Q, Zhan S, Chen P, Liu W, Lv J, et al. LKB1 dictates sensitivity to immunotherapy through Skp2-mediated ubiquitination of PD-L1 protein in non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-009444

BibTeX
@article{Lv2024,
  author = {Lv, Liting and Miao, Qing and Zhan, Sutong and Chen, Peilin and Liu, Wei and Lv, Jiawen and Yan, Wenjie and Wang, Dong and Liu, Hongbing and Yin, Jie and Feng, Jian and Song, Yong and Ye, Mingxiang and Lv, Tangfeng},
  title = {LKB1 dictates sensitivity to immunotherapy through Skp2-mediated ubiquitination of PD-L1 protein in non-small cell lung cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2024-009444}
}
Kostenlos starten →